A number of therapeutic strategies are being investigated in human OA patients to target the remodeling process in OA subchondral bone, for example, bisphosphonates and strontium ranelate (used also for the prevention and treatment of osteoporosis by inhibiting osteoclast activity and enhancing osteoblasts), and cathepsin K inhibitors, which may act on both cartilage and subchondral bone remodeling (5). Here, CTSK is linked to osteoporosis.